Diagnostic Accuracy of FibroScan-AST (FAST) Score for Identifying Severe Nonalcoholic Steatohepatitis in a Greek Cohort.
作者信息
Savvidou Savvoula, Goulis Ioannis
机构信息
Hepatology Outpatient Clinic, 4th Department of Internal Medicine, Medical School of Aristotle University of Thessaloniki, Hippocration University Hospital of Thessaloniki, Greece.
出版信息
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1162-1164. doi: 10.1016/j.jceh.2023.06.011. Epub 2023 Jul 7.
Abstract
摘要
相似文献
1
Diagnostic Accuracy of FibroScan-AST (FAST) Score for Identifying Severe Nonalcoholic Steatohepatitis in a Greek Cohort.FibroScan-AST（FAST）评分在希腊队列中识别重度非酒精性脂肪性肝炎的诊断准确性
J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1162-1164. doi: 10.1016/j.jceh.2023.06.011. Epub 2023 Jul 7.
2
FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.非酒精性脂肪性肝炎的FibroScan-AST（FAST）评分——在印度队列中的验证
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):440-447. doi: 10.1016/j.jceh.2021.06.008. Epub 2021 Jun 15.
3
Diagnostic accuracy of FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis in patients with chronic hepatitis B with metabolic dysfunction-associated fatty liver disease.诊断准确性的 FibroScan-AST (FAST) 评分、非酒精性脂肪性肝纤维化评分 (NFS)、FibroScan 和肝纤维化指数 (FIB-4) 在识别代谢相关脂肪性肝病合并慢性乙型肝炎患者的纤维化非酒精性脂肪性肝炎。
Ann Med. 2024 Dec;56(1):2420858. doi: 10.1080/07853890.2024.2420858. Epub 2024 Oct 26.
4
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.在北美队列中验证FAST™评分检测有非酒精性脂肪性肝炎（NASH）风险患者的准确性，并与其他非侵入性算法进行比较。
PLoS One. 2022 Apr 15;17(4):e0266859. doi: 10.1371/journal.pone.0266859. eCollection 2022.
5
Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.FibroScan-AST（FAST）评分对纤维化非酒精性脂肪性肝炎患者非侵入性识别的诊断准确性：系统评价和荟萃分析。
Gut. 2023 Jul;72(7):1399-1409. doi: 10.1136/gutjnl-2022-328689. Epub 2023 Jan 4.
6
Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes.FibroScan-AST评分对日本非酒精性脂肪性肝病患者中具有显著活动和纤维化的非酒精性脂肪性肝炎的诊断准确性：M型和XL型探头的比较
Hepatol Res. 2020 Jul;50(7):831-839. doi: 10.1111/hepr.13508. Epub 2020 May 13.
7
M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis.在诊断活动性纤维化非酒精性脂肪性肝炎方面，M-PAST评分优于MAST评分。
Hepatol Res. 2023 Sep;53(9):844-856. doi: 10.1111/hepr.13927. Epub 2023 Jun 15.
8
Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis.2型糖尿病患者血清可溶性二肽基肽酶-4水平与通过瞬时弹性成像（FibroScan）和FAST（FibroScan-AST）评分评估的肝纤维化严重程度相关，FAST评分是一种用于评估伴有显著纤维化的非酒精性脂肪性肝炎的新指标。
J Diabetes Complications. 2021 May;35(5):107885. doi: 10.1016/j.jdiacomp.2021.107885. Epub 2021 Feb 6.
9
Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.临床纤维化标志物、Hepascore 和 Fibroscan®对非酒精性脂肪性肝病患者诊断肝纤维化的准确性比较。
Dig Dis Sci. 2023 Jun;68(6):2757-2767. doi: 10.1007/s10620-023-07896-3. Epub 2023 Mar 22.
10
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. FibroScan-AST (FAST) 评分用于无创识别有显著活动度和纤维化的非酒精性脂肪性肝炎患者：一项前瞻性推导和全球验证研究。
Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3.
本文引用的文献
1
Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.基于 FibroScan 的 Agile 评分增强对非酒精性脂肪性肝病患者肝纤维化和肝硬化的诊断。
J Hepatol. 2023 Feb;78(2):247-259. doi: 10.1016/j.jhep.2022.10.034. Epub 2022 Nov 12.
2
Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.2021年欧洲肝脏研究学会（EASL）非酒精性脂肪性肝病（NAFLD）晚期纤维化无创诊断新算法的验证
Hepatology. 2023 Mar 1;77(3):920-930. doi: 10.1002/hep.32665. Epub 2023 Feb 17.
3
FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.非酒精性脂肪性肝炎的FibroScan-AST（FAST）评分——在印度队列中的验证
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):440-447. doi: 10.1016/j.jceh.2021.06.008. Epub 2021 Jun 15.
4
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.EASL 临床实践指南：非侵入性检测评估肝脏疾病严重程度和预后——2021 更新版。
J Hepatol. 2021 Sep;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025. Epub 2021 Jun 21.
5
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. FibroScan-AST (FAST) 评分用于无创识别有显著活动度和纤维化的非酒精性脂肪性肝炎患者：一项前瞻性推导和全球验证研究。
Lancet Gastroenterol Hepatol. 2020 Apr;5(4):362-373. doi: 10.1016/S2468-1253(19)30383-8. Epub 2020 Feb 3.
6
Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.FLIP算法和SAF评分在非酒精性脂肪性肝病患者中的临床验证。
J Hepatol. 2020 May;72(5):828-838. doi: 10.1016/j.jhep.2019.12.008. Epub 2019 Dec 17.
7
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.组织学疾病活动与非酒精性脂肪性肝病进展的关联。
JAMA Netw Open. 2019 Oct 2;2(10):e1912565. doi: 10.1001/jamanetworkopen.2019.12565.
8
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.利拉鲁肽治疗非酒精性脂肪性肝炎（LEAN）患者的安全性和有效性：一项多中心、双盲、随机、安慰剂对照的 2 期研究。
Lancet. 2016 Feb 13;387(10019):679-690. doi: 10.1016/S0140-6736(15)00803-X. Epub 2015 Nov 20.
Zotero 插件